Live Attenuated Influenza Vaccine as a Nasal Model for Influenza Infection
NCT ID: NCT04164212
Last Updated: 2025-12-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE4
25 participants
INTERVENTIONAL
2020-09-01
2026-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
open label
FLUMIST QUADRIVALENT 0.2 mL dose supplied in a single-dose pre-filled intranasal sprayer
Flumist Quadrivalent Nasal Product
FLUMIST QUADRIVALENT 0.2 mL dose supplied in a single-dose pre-filled intranasal sprayer
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Flumist Quadrivalent Nasal Product
FLUMIST QUADRIVALENT 0.2 mL dose supplied in a single-dose pre-filled intranasal sprayer
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* not yet received influenza vaccine for 2019-2020, and
* capable of giving signed informed consent.
Exclusion Criteria
* active smoking within past 6 months,
* asthma, chronic lung/liver/kidney /neurologic/hematologic/metabolic disorders,cardiovascular disease (excluding isolated hypertension), diabetes mellitus, disease, congestive heart failure,
* pregnancy,
* current or recent (within the past month) upper/lower respiratory tract infection, chronic sinusitis/nasal allergies requiring frequent or daily therapy (including topical corticosteroids),
* prior adverse reaction to influenza vaccine,
* history of Guillain-Barre syndrome,
* egg allergy,
* close contact with an individual with severe immunodeficiency/immunosuppression.
18 Years
49 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Alabama at Birmingham
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
David Lafon
Clinical Instructor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UAB Lung Health Center
Birmingham, Alabama, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
David LaFon, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRB-300004274
Identifier Type: -
Identifier Source: org_study_id